Effect of MitoQ versus placebo on serum the level of oxidative stress biomarkers in patients with early septic shock

Effect of MitoQ versus placebo on serum the level of oxidative stress biomarkers in patients with early septic shock: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N500

Enrollment

Registered

2024-02-29

Start date

2024-04-03

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early septic shock. Severe sepsis with septic shock

Interventions

Intervention 1: Intervention group: Routine treatment with MitoQ capsules 20 mg every 12 hours for 5 days. Intervention 2: Control group: Routine treatment plus placebo capsules every 12 hours for 5 d

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18 to 65 years Premature septic shock Receive vasopressor for at least 6 and maximum for 24 hours

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Treated with other antioxidant and anti-inflammatory drugs Chronic liver or kidney disease

Design outcomes

Primary

Measure	Time frame
The serum level of catalase enzyme. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By Catalase Activity Assay (CAA).;Serum level of glutathione peroxidase enzyme. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Glutathione Peroxidase (GPx) Activity Assay.;Serum level of total antioxidant capacity. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Total Antioxidant Capacity (TAC) Assay.;Malonaldehyde serum level. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Oxygen Radical Absorbance Capacity (ORAC) assay.;Serum levels of thiol groups. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Ellman's assay.;Serum levels of iron and ferritin. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Total Iron-Binding Capacity (TIBC) Measurement and the enzyme-linked immunosorbent assay (ELISA).	—

Measure

Time frame

The serum level of catalase enzyme. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By Catalase Activity Assay (CAA).;Serum level of glutathione peroxidase enzyme. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Glutathione Peroxidase (GPx) Activity Assay.;Serum level of total antioxidant capacity. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Total Antioxidant Capacity (TAC) Assay.;Malonaldehyde serum level. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Oxygen Radical Absorbance Capacity (ORAC) assay.;Serum levels of thiol groups. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Ellman's assay.;Serum levels of iron and ferritin. Timepoint: Before the intervention and on the third and fifth days after the intervention. Method of measurement: By the Total Iron-Binding Capacity (TIBC) Measurement and the enzyme-linked immunosorbent assay (ELISA).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHanieh Hasani Pajoo

Hamedan University of Medical Sciences

hasani.h.79@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026